ATHERSYS, INC / NEW Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018
Current assets:
Cash and cash equivalents
Accounts receivable from Healios
Healios License Agreement
Consolidated entity, excluding related party
Affiliated Entity
Total accounts receivable from Healios

Unbilled accounts receivable from Healios
Healios License Agreement
Affiliated Entity
Unbilled accounts receivable from Healios
Affiliated Entity
Total unbilled accounts receivable from Healios
Prepaid clinical trial costs
Prepaid expenses and other
Total current assets
Operating right-of-use assets, net
Property and equipment, net
Deposits and other
Other Assets
Total assets

Current liabilities:
Accounts payable
Consolidated entity, excluding related party
Affiliated Entity
Total accounts payable
Accounts payable to Healios
Affiliated Entity
Total accounts payable to Healios
Deferred accounts payable to Supplier
Operating lease liabilities, current
Accrued compensation and related benefits
Accrued license fee expense
Deposit from Healios
Accrued clinical trial related costs
Accrued expenses and other
Note Payable
Deferred revenue - Healios
Affiliated Entity
Healios License Agreement
Total affiliated Entity

Total deferred revenue - Healios
Warrant liability
Affiliated Entity
Total warrant liability
Total current liabilities

Accounts payable to Healios, non-current
Operating lease liabilities, non-current
Advance from Healios
Healios License Agreement
Affiliated Entity
Total advance from Healios

Other long-term liabilities
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock, $0.001 par value; 600,000,000 shares authorized with 26,758,431 and 17,986,147 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Additional paid-in capital
Stock subscription receivable from Healios
Accumulated deficit
Accumulated other comprehensive income
Total stockholders’ deficit
Total liabilities and stockholders’ equity
Deferred Accounts Payable To Supplier

Comments